ClinicalTrials.gg
CompletedNCT01241344Updated Jul 21, 2021Results posted

Phase 2 Study to Evaluate Brincidofovir for the Prevention of Adenovirus Disease

A Phase 2 interventional study of Brincidofovir and Placebo in Adenovirus Disease, sponsored by Chimerix. Completed at 30 sites in United States. Open to participants aged 3 Months to 75 Years. Per ClinicalTrials.gov, last updated 2021-07-21.

Sponsored by Chimerix (part of Jazz Pharmaceuticals) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
3 Months to 75 Years
Sex
All
01

Study summary

This study was designed to assess the safety and efficacy of preemptive treatment with oral brincidofovir (BCV), as compared to placebo, for the prevention of adenovirus (AdV) disease in recipients of hematopoietic stem cell transplantation (HCT) with asymptomatic AdV viremia.

Read the detailed description

This was a Phase 2, randomized, multicenter, placebo-controlled study for pediatric and adult subjects who had undergone hematopoietic stem cell transplantation (HCT) and who had been identified as having asymptomatic adenovirus (AdV) viremia [i.e., had detectable AdV DNA in plasma based on polymerase chain reaction testing performed at the local laboratory with no AdV disease symptoms]. The primary objectives of the study were to assess the safety and tolerability of oral brincidofovir (BCV), and to estimate the treatment failure rate based on an efficacy endpoint with 2 different dosing regimens of oral BCV versus placebo.

02

Conditions studied

  • Adenovirus Disease

Keywords

  • AdV
  • Hematopoeitic Stem Cell Transplant
  • HSCT
03

In context

Lead sponsor

Chimerix is the lead sponsor of 33 studies on the registry; none are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 6 (86%) have results posted.

First submitted before Chimerix became part of Jazz Pharmaceuticals.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Months to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For inclusion into the study, subjects were required to fulfill all of the following criteria:

  1. Were males or female aged ≥3 months to ≤75 years.
  2. Received an hematopoietic stem cell transplant (HCT).
  3. Had positive serum adenovirus (AdV) PCR (>100 copies/mL) as measured by the central laboratory (unless the subject developed AdV disease while participating in the prescreening activities and after concurrence from the Chimerix medical monitor or designee).
  4. Was on dialysis during treatment if he/she had an estimated (eGFR) ≤30 mL/minute.
  5. Subject or guardian(s) were willing to comply with the protocol.
  6. Subject or guardian(s) were willing and able to understand the /assent.
  7. Female subjects of must have had a negative pregnancy test and must have agreed to use 2 acceptable methods of throughout the study with at least 1 being a barrier method. Sexually active males of procreation potential must have been able and willing to se a reliable and medically approved contraceptive method throughout the study. At least 1 barrier method of contraception must have been used.

Exclusion criteria

Exclusion Criteria

Subjects meeting any of the following exclusion criteria were excluded from participation in the study:

  1. Had possible, probable, or definitive AdV disease (unless the subject developed probable or definitive AdV disease while participating in prescreening activities and after concurrence from he Chimerix medical monitor or designee).
  2. Had suspected gut that was not -proven (subjects with a biopsy performed were included in the study).
  3. Had an ≤30 mL/minute and was not currently on dialysis.
  4. Had an or aspartate aminotransferase >5 x the (ULN), total ≥2 x the ULN, or conjugated (direct) bilirubin ≥1.5 x the ULN.
  5. Had a condition that prevented oral dosing of study drug.
  6. Was antibody positive, based upon available medical records.
  7. Had ocular hypotony, uveitis, or retinitis or any other intraocular pathology that would have predisposed the subject to 1 of these conditions.
  8. Had participated in another clinical study of an drug/biologic or was exposed to an investigational drug/biologic within 30 days of enrollment without the prior written approval of the Chimerix medical monitor or designee. For subjects who were participating in any clinical study involving non-investigational drugs and/or biologics, the investigator must have obtained approval from the Chimerix medical monitor or designee prior to enrolling the subject.
  9. Was pregnant or breast-feeding or intended to conceive during the course of the study, including the follow-up period after drug discontinuation.
  10. Had known immunologic to cidofovir (CDV) or brincidofovir (BCV) drug or any of its .
  11. Had a history of illicit drug use or alcohol abuse within the previous 6 months.
  12. Had any medical condition that, in the opinion of the investigator, might have interfered with the subject's participation in the study, posed an added risk for the subject, or confounded the assessment of the subject (e.g. severe cardiovascular, central nervous system or pulmonary disease).
  13. Received BCV, CDV, ribavirin, or leflunomide within the previous 14 days.
  14. Was receiving or was anticipated to need treatment with digoxin that could not have been withheld for the duration of BCV therapy.

Any exemptions to the protocol inclusion or exclusion criteria, as applicable, for subjects who developed probably or definitive AdV disease while participating in prescreening activities must have been discussed with and approved by the Chimerix medical monitor or designee before the subject was allowed to receive open-label BCV therapy.

Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
52 participants (actual)

Study arms

  • Active comparator
    Brincidofovir

    * Adult subjects: 200mg BCV administered as 50mg tablets taken orally either once weekly (QW; 4 tablets) or twice weekly (BIW; 2 tablets). * Pediatric subjects: 4mg/kg BCV (not to exceed a total single dose of 200mg) administered using a 10 mg/mL liquid formulation taken orally either QW (as 4 mg/kg) or BIW (as 2 mg/kg).

    Drug: Brincidofovir

  • Placebo comparator
    Placebo

    * Adult subjects: Matching placebo tablets taken orally either once weekly (QW; 4 tablets) or twice weekly (BIW; 2 tablets). * Pediatric subjects: Matching liquid placebo taken orally either QW (as 4 mg/kg) or BIW (as 2 mg/kg).

    Other: Placebo

Interventions

  • * Adult subjects: 200mg BCV administered as 50mg tablets taken orally either once weekly (QW; 4 tablets) or twice weekly (BIW; 2 tablets). * Pediatric subjects: 4mg/kg BCV (not to exceed a total single dose of 200mg) administered using a 10 mg/mL liquid formulation taken orally either QW (as 4 mg/kg) or BIW (as 2 mg/kg).

    Also known as: BCV, CMX001

  • OtherPlacebo

    Adult subjects: Matching placebo tablets taken orally either once weekly (QW; 4 tablets) or twice weekly (BIW; 2 tablets). • Pediatric subjects: Matching liquid placebo taken orally either QW (as 4 mg/kg) or BIW (as 2 mg/kg).

06

What researchers measure

Primary outcomes

  1. Number of Participants With Clinically Significant AdV Infection

    The primary objective of this study was to evaluate the safety and efficacy of preemptive treatment with brincidofovir (BCV) versus placebo for the prevention of adenovirus (AdV) disease in recipients of hematopoietic stem cell transplantation (HCT) with asymptomatic AdV viremia. The outcome measure for the primary endpoint was treatment failure, a composite endpoint that consisted of the following: * Progression to probable AdV disease (other positive causes/agents have been ruled out and subject has disease-targeted organ-specific signs or symptoms) or definitive AdV disease (AdV detected in disease-targeted organ/system biopsy via antigen/immunohistochemistry, culture, and/or polymerase chain reaction and has at least 1 disease-targeted organ-specific sign or symptom); or * Increasing AdV viremia (defined as an increase from baseline in AdV viremia by ≥1 log10, confirmed on a second measurement, at least 1 week apart) and requiring discontinuation from blinded therapy.

    Time frame: 12 weeks

07

Results

Posted Jul 16, 2021

Participant flow

Participant flow — Overall Study
MilestoneBrincidofovir BIWBrincidofovir QWPlaceboDirectly to Open-label
Started1416184
Randomized to open-label3450
Completed9792
Not completed5992

Outcome measures

PrimaryNumber of Participants With Clinically Significant AdV Infection

The primary objective of this study was to evaluate the safety and efficacy of preemptive treatment with brincidofovir (BCV) versus placebo for the prevention of adenovirus (AdV) disease in recipients of hematopoietic stem cell transplantation (HCT) with asymptomatic AdV viremia. The outcome measure for the primary endpoint was treatment failure, a composite endpoint that consisted of the following: * Progression to probable AdV disease (other positive causes/agents have been ruled out and subject has disease-targeted organ-specific signs or symptoms) or definitive AdV disease (AdV detected in disease-targeted organ/system biopsy via antigen/immunohistochemistry, culture, and/or polymerase chain reaction and has at least 1 disease-targeted organ-specific sign or symptom); or * Increasing AdV viremia (defined as an increase from baseline in AdV viremia by ≥1 log10, confirmed on a second measurement, at least 1 week apart) and requiring discontinuation from blinded therapy.

Time frame:
12 weeks
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant AdV Infection
ParticipantsBCV BIWBCV QWPlacebo
Number of Participants With Clinically Significant AdV Infection366

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BCV BIW—6/14 (42.9%)13/14 (92.9%)
BCV QW—7/16 (43.8%)14/16 (87.5%)
Placebo—6/18 (33.3%)16/18 (88.9%)
BCV Open-Label—8/12 (66.7%)12/12 (100%)
Most frequent serious events
Showing 10 of 44
Most frequent serious events
EventBCV BIWBCV QWPlaceboBCV Open-Label
Respiratory failureRespiratory, thoracic and mediastinal disorders0/141/160/182/12
DiarrhoeaGastrointestinal disorders2/141/160/182/12
Acute graft versus host diseaseImmune system disorders2/142/161/181/12
HypotensionVascular disorders1/140/160/181/12
Portal vein thrombosisHepatobiliary disorders0/140/160/181/12
Renal failure acuteRenal and urinary disorders0/140/160/181/12
Multi-organ failureGeneral disorders0/140/160/181/12
Enterococcal bacteraemiaInfections and infestations0/140/160/181/12
Enterococcal sepsisInfections and infestations0/140/160/181/12
Septic shockInfections and infestations0/140/160/181/12
Most frequent other events
Showing 10 of 207
Most frequent other events
EventBCV BIWBCV QWPlaceboBCV Open-Label
DiarrhoeaGastrointestinal disorders8/146/165/186/12
Acute graft versus host diseaseImmune system disorders7/144/163/185/12
NauseaGastrointestinal disorders2/142/164/185/12
Enterococcal bacteraemiaInfections and infestations0/140/160/183/12
VomitingGastrointestinal disorders1/144/164/183/12
Abdominal painGastrointestinal disorders2/140/162/183/12
Respiratory distressRespiratory, thoracic and mediastinal disorders1/140/160/183/12
PyrexiaGeneral disorders3/143/164/183/12
HypokalaemiaMetabolism and nutrition disorders1/140/163/183/12
HypophosphataemiaMetabolism and nutrition disorders0/140/160/183/12

Baseline characteristics

Subjects in the Brincidofovir (BCV) BIW, BCV QW, and Placebo groups were randomized subjects who took at least 1 dose of study drug. Subjects in the BCV Open-Label group included 4 subjects who were not randomized and went directly into open-label, and 8 subjects from the BCV BIW and BCV QW groups. The baseline data represents the 4 subjects who were not previously randomized to the BCV BIW or BCV QW groups.

Age, Continuous
Age, Continuous(years)BCV BIWBCV QWPlaceboBCV Direct to Open-LabelTotal
Mean12.6 ± 14.6415.7 ± 20.6713.8 ± 12.3523.8 ± 21.5514.8 ± 16.44
Sex: Female, Male
Sex: Female, Male(Participants)BCV BIWBCV QWPlaceboBCV Direct to Open-LabelTotal
Female537015
Male91311437
08

Study locations

30 sites
  • Children's Hospital of Alabama
    Birmingham, Alabama 35233, United States
  • Pheonix Children's Hospital
    Phoenix, Arizona 85016, United States
  • City of Hope National Medical Center
    Duarte, California 91010, United States
  • Childrens hospital of LA
    Los Angeles, California 90033, United States
  • CHOC Children's Hospital
    Orange, California 92868, United States
  • University of California, San Francisco
    San Francisco, California 94143, United States
  • Lucile Packard Childrens hopsital at Stanford
    Stanford, California 94304, United States
  • The Children's Hospital-Denver
    Aurora, Colorado 80045, United States
  • Children's National Medical Center
    Washington, District of Columbia 20010, United States
  • Indiana University
    Indianapolis, Indiana 46202, United States
  • LSU Health Sciences Center New Orleans Childrens Hospital
    New Orleans, Louisiana 70118, United States
  • Harvard-Children's Hospital Boston
    Boston, Massachusetts 02115, United States
  • Univeristy of Minnesota
    Minneapolis, Minnesota 55455, United States
  • St. Louis Children's Hosptial
    Saint Louis, Missouri 63110, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Memorial Sloan Kettering
    New York, New York 10021, United States
  • New York Medical College
    Valhalla, New York 10595, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Cincinnati Childrens Hospital
    Cincinnati, Ohio 45229, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • The Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Children's Hospital of Pittsburgh of UPMC
    Pittsburgh, Pennsylvania 15224, United States
  • St. Judes Children's Research Hospital
    Memphis, Tennessee 38105, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • UT Southwestern
    Dallas, Texas 75390, United States
  • Baylor College of Medicine, Texas Childrens Hospital
    Houston, Texas 77030, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Methodist Hospital
    San Antonio, Texas 78229, United States
  • Primary Children's Medical of Utah
    Salt Lake City, Utah 84113, United States
  • Seattle Cancer Care Alliance
    Seattle, Washington 98109, United States
09

References and documents

Publications

  • Grimley MS, Chemaly RF, Englund JA, Kurtzberg J, Chittick G, Brundage TM, Bae A, Morrison ME, Prasad VK. Brincidofovir for Asymptomatic Adenovirus Viremia in Pediatric and Adult Allogeneic Hematopoietic Cell Transplant Recipients: A Randomized Placebo-Controlled Phase II Trial. Biol Blood Marrow Transplant. 2017 Mar;23(3):512-521. doi: 10.1016/j.bbmt.2016.12.621. Epub 2017 Jan 5. PubMed 28063938 ↗
  • Tippin TK, Morrison ME, Brundage TM, Mommeja-Marin H. Brincidofovir Is Not a Substrate for the Human Organic Anion Transporter 1: A Mechanistic Explanation for the Lack of Nephrotoxicity Observed in Clinical Studies. Ther Drug Monit. 2016 Dec;38(6):777-786. doi: 10.1097/FTD.0000000000000353. PubMed 27851688 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2010 to primary completion in Jun 2013, 31 months.

Results were first posted in Jul 2021, 8 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2010
First posted
Nov 16, 2010
StartActual
Nov 2010
Primary completionActual
Jun 2013
CompletionActual
Jun 2013
Results first posted
Jul 16, 2021
Last update
Jul 21, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01241344
Lead sponsor
Chimerix
Responsible party
Sponsor
First posted
Nov 16, 2010
Start date
Nov 2010
Primary completion
Jun 2013
Completion
Jun 2013
Results posted
Jul 16, 2021
Last update
Jul 21, 2021

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brincidofovir

Start the discussion